

## SUBJECT INDEX VOLUME-1

|   |         |  |     |
|---|---------|--|-----|
| Acute graft-versus-host disease (aGVHD) .....           | 203     | challenge in .....                                   | 213 |
| activation/early expansion of donor T cells in .....    | 204     | gene therapy for .....                               | 219 |
| chemokines in .....                                     | 206     | mesenchymal stem cells for .....                     | 215 |
| cytokines in .....                                      | 206     | scaffolds for .....                                  | 218 |
| inflammatory environment in .....                       | 203     | Autoimmune disease .....                             | 279 |
| injury of target tissues in .....                       | 205     | haematopoietic stem cell gene therapy to treat ..... | 279 |
| mesenchymal stem cells (MSC) for .....                  | 208     | Autoimmunity .....                                   | 279 |
| natural killer (NK) cells in .....                      | 207     | development of .....                                 | 280 |
| role of naturally occurring regulatory CD4 <sup>+</sup> |         | role in allogeneic haematopoietic stem cell          |     |
| CD25 <sup>+</sup> T cells .....                         | 208     | transplants .....                                    | 281 |
| T cell trafficking/determination of target              |         | role in autologous haematopoietic stem cell          |     |
| tissues in .....  | 204     | transplants .....                                    | 281 |
| Adipose-derived stem cells .....                        | 13      | self-reactivity of .....                             | 280 |
| in tissue engineering .....                             | 16      | thymic tolerance in .....                            | 280 |
| in tissue transplantation .....                         | 13      | Bio-engineered tissues .....                         | 337 |
| Adult bone marrow derived cells (BMCS) stem cells ..... | 5       | strategies for generation of .....                   | 337 |
| advantages to transplantation .....                     | 5       | Bone/cartilage .....                                 | 346 |
| limitations of .....                                    | 5       | biology of .....                                     | 346 |
| Adult cardiac stem (ACS) cells .....                    | 6       | Bone/soft-tissue sarcomas .....                      | 29  |
| advantages of .....                                     | 6       | dose-intensive chemotherapy for .....                | 29  |
| limitations of .....                                    | 6       | stem cell support for .....                          | 29  |
| recommendations of .....                                | 6       | treatment strategy for .....                         | 29  |
| Adult mesenchymal stem cells .....                      | 365     | Bone marrow derived cells .....                      | 282 |
| applications of .....                                   | 365     | ectopic expression of autoantigen in .....           | 282 |
| differentiative capabilities of .....                   | 366     | Bone marrow transplants .....                        | 321 |
| isolation/characterization of .....                     | 365     | Brain .....  | 65  |
| therapeutic potential of .....                          | 366     | genomic/transcriptomic screening of .....            | 67  |
| Adult skeletal myoblast cells .....                     | 4       | screening of .....                                   | 65  |
| advantages of .....                                     | 4       | stem cells in .....                                  | 66  |
| limitations of .....                                    | 4       | Brain repair .....                                   | 55  |
| recommendations of .....                                | 4       | imaging to elucidate stem cell-mediated .....        | 55  |
| Adult stem cells .....                                  | 157,345 | neuroimaging in .....                                | 55  |
| activation of .....                                     | 159     | stem cell-mediated .....                             | 55  |
| adipose tissue derived .....                            | 354     | Cachexia .....                                       | 166 |
| differentiation of .....                                | 159     | Cancer stem cells .....                              | 43  |
| in allogeneic transplantation .....                     | 358     | application of .....                                 | 43  |
| in bone/cartilage tissue engineering .....              | 345,349 | Cardiac disease .....                                | 7   |
| in tissue engineering in bone/cartilage                 |         | stem cell type to use for .....                      | 7   |
| regenerative medicine .....                             | 347     | Cardiology .....                                     | 1   |
| in myogenic lineage .....                               | 164     | application of stem cells in .....                   | 1   |
| proliferation of .....                                  | 159     | Cell enhancer .....                                  | 387 |
| recruitment of .....                                    | 164     | Cell transformer .....                               | 387 |
| regulation of .....                                     | 159     | Cellular fusion .....                                | 415 |
| repair market of .....                                  | 347     | Chondrogenic gene therapy .....                      | 213 |
| repair of .....   | 159     | Cloning .....  | 132 |
| skeletal muscle derived .....                           | 355     | to produce genetically identical stem cells .....    | 132 |
| therapeutic potential of skeletal muscle .....          | 157     | Combination cord blood .....                         | 321 |
| Adult stem/progenitor cells .....                       | 431     |  |     |
| Allogeneic hematopoietic cell transplantation           |         |  |     |
| (aHCT) .....  | 203,    |  |     |
| application of .....                                    | 203     |  |     |
| non-HLA gene polymorphisms of .....                     | 239     |  |     |
| Allograft transplantation .....                         | 123     |  |     |
| tolerogenic DC in preclinical models of .....           | 123     |  |     |
| Articular cartilage repair .....                        | 213     |  |     |
| cartilage tissue engineering for .....                  | 215     |  |     |

|   |               |   |         |
|---|---------------|---|---------|
| Cord blood .....  | 356           | Endothelial cells .....                       | 333     |
| Corneal epithelium .....  | 231           | application of .....                          | 338     |
| Cryopreservation .....  | 48            | in neovascularization .....                   | 333     |
| Cryopreserving human peripheral blood progenitor<br>cells ..... | 47            | in therapeutic angiogenesis .....             | 333     |
| CXCR-4/SDF-1 .....  | 81            | in tissue engineering .....                   | 333     |
| sources for .....   | 82            | Epidermal growth factor receptor (EGFR) ..... | 387     |
| Cytokines .....   | 159           | signaling in adult gliomagenesis .....        | 390     |
| in skeletal muscle inflammation/repair .....                    | 159           | signaling in adult neurogenesis .....         | 389     |
| Dendritic cell therapy .....                                    | 121           | targeting for brain tumor therapy .....       | 391     |
| for tolerance induction to stem cell transplants ....           | 121           | to determine NSC phenotype/behavior .....     | 387     |
| to induce tolerance .....                                       | 122           | Epithelial stem cells .....                   | 113     |
| Developmental plasticity .....                                  | 85            | in tissue engineered intestine .....          | 113     |
| Diabetes mellitus .....   | 255           | intestinal .....                              | 114     |
| as target for stem cell therapy .....                           | 255           | lineages of small intestine/colon .....       | 114     |
| replacement $\beta$ -cells in .....                             | 256           | ESC derived cell transplants .....            | 130     |
| xenografts in .....   | 259           | preclinical trials of .....                   | 130     |
| Dose-intensive chemotherapy .....                               | 30            | Experimental autoimmune diseases .....        | 282     |
| rationale/prerequisites for .....                               | 30            | Fetal cell .....                              | 377     |
| with stem cell support .....                                    | 30            | in gene therapy .....                         | 377     |
| Embryogenesis .....   | 146           | Fetal haemopoiesis .....                      | 371     |
| Embryonic stem (ES) cells .....                                 | 1,103,139,425 | Fetal pancreas .....                          | 430     |
| advantages of .....   | 2             | Follicular atresia .....                      | 294     |
| cell engineering of .....                                       | 8             | Growth factors .....                          | 333     |
| crosstalk between intracellular signaling                       |               | angiogenic type .....                         | 334     |
| pathways of .....   | 108           | angiopoietin as .....                         | 336     |
| gastrulation/definitive endoderm differentiation                |               | fibroblast growth factor as .....             | 334     |
| from .....  | 148           | hepatocyte growth factor as .....             | 335     |
| hepatic differentiation of .....                                | 139           | hypoxia-inducible factor-1 as .....           | 336     |
| hepatocyte differentiation from .....                           | 148,150       | in therapeutic angiogenesis .....             | 333     |
| in cell differentiation .....                                   | 150           | in tissue engineering .....                   | 333     |
| in hepatocyte differentiation .....                             | 144           | indirect angiogenic factors as .....          | 335     |
| in liver development .....                                      | 144           | platelet-derived growth factor as .....       | 335     |
| intracellular signaling pathways regulating                     |               | transforming growth factor as .....           | 335     |
| pluripotency of .....   | 103           | vascular endothelial growth factor as .....   | 334     |
| limitations of .....  | 3             | Growth plate cartilage repair .....           | 214     |
| recommendations of .....  | 4             | cartilage tissue engineering for .....        | 215     |
| regenerative medicine for .....                                 | 139           | challenges in .....                           | 214     |
| role of BMP/Smad in .....                                       | 104           | gene therapy for .....                        | 219     |
| role of epigenetic modification in .....                        | 109           | mesenchymal stem cells for .....              | 215     |
| role of LIF/gp130/STAT3 in .....                                | 103           | Hematopoiesis .....                           | 305     |
| role of phosphatidylinositol 3 (PI3) kinase in ....             | 106           | Haematopoietic stem cells (HSC) .....         | 279,305 |
| role of Ras/Raf/ERK in .....                                    | 107           | cell fate decision of .....                   | 307     |
| role of Wnt/ $\beta$ -catenin/TCF in .....                      | 105           | cell surface markers for .....                | 305     |
| transcription factors controlling                               |               | characterization of .....                     | 305     |
| self-renewal of .....   | 109           | extrinsic regulation of .....                 | 310     |
| treatment of .....  | 139           | fetal sheep/non-human primate models of ..... | 307     |
| Endoderm differentiation .....                                  | 142           | in immunological tolerance .....              | 281     |
| in early mouse embryo .....                                     | 142           | <i>in vitro</i> culture assays for .....      | 306     |
| Endogenous progenitor .....                                     | 79            | <i>in vivo</i> assay for .....                | 307     |
| migration of .....  | 79            | induction of immunological tolerance using    |         |
|   |               | genetically modified .....                    | 282     |

|  |         |  |              |
|--|---------|--|--------------|
| intrinsic regulation on .....              | 308     | Mesenchymal stem cell .....                        | 21,213,349   |
| isolation of .....                         | 305     | based chondrogenesis .....                         | 217          |
| metabolic markers for .....                | 306     | based HLA-independent cell therapy .....           | 21           |
| regulation at genome wide scale .....      | 312     | bone marrow derived .....                          | 349          |
| regulation of cell fate decision of .....  | 308     | for tissue engineering of bone/cartilage .....     | 21           |
| stem cell model of .....                   | 305     | growth plate cartilage using .....                 | 213          |
| Hodgkin's disease .....                    | 419     | in bone regeneration .....                         | 22           |
| allogeneic transplantation for .....       | 422     | in cartilage repair .....                          | 24           |
| induction regimens in .....                | 420     | in repair of injured articular .....               | 213          |
| mobilizing ability in .....                | 421     | in tissue engineering .....                        | 22,351       |
| resistant/relapsing type .....             | 419     | sources of .....                                   | 215          |
| HSP70-HOM .....                            | 248     | Molecular fingerprints .....                       | 65           |
| Human embryonic stem cells .....           | 173     | Multipotent adult stem cells-muscle .....          | 162          |
| derived cardiomyocytes .....               | 176     | Muscle derived stem cells .....                    | 356          |
| differentiation of .....                   | 173     | Muscle satellite cells .....                       | 355          |
| for cardiac cell replacement therapy ..... | 173     | Muscle stem cell therapy .....                     | 167          |
| growth of .....                            | 173     | clinical applications of .....                     | 167          |
| therapies by .....                         | 181     | Myoblasts .....                                    | 165          |
| transplantation of .....                   | 179     | Myotubes .....                                     | 166          |
| Human fetal mesenchymal stem cells .....   | 371     | DE-differentiation of .....                        | 166          |
| ageing of .....                            | 376     | Neural stem cells .....                            | 55,65,79,267 |
| as vehicles for gene delivery .....        | 378     | cell intrinsic programs involved in regulating     |              |
| biology of .....                           | 375     | fate of .....                                      | 272          |
| comparison with MSC derived from umbilical |         | cell-extrinsic cues in fate determination of ..... | 267          |
| cord blood .....                           | 377     | cytokines in .....                                 | 268          |
| immunology of .....                        | 376     | fate determination of .....                        | 267          |
| in ongoing pregnancies .....               | 379     | for tumors .....                                   | 79           |
| IFN-gamma .....                            | 247     | functional anatomy of repair by .....              | 59           |
| IL-10 .....                                | 246     | genomic/transcriptomic studies of .....            | 68           |
| IL-6 .....                                 | 245     | in therapy for brain tumors .....                  | 79           |
| Intestinal tissue engineering .....        | 115     | molecular fingerprints of .....                    | 65           |
| Ischemic tissues .....                     | 336     | proteomics of .....                                | 72           |
| therapeutic angiogenesis for .....         | 336     | role of transcriptional factors in .....           | 271          |
| Leukemic stem cell .....                   | 312     | to promote behavioral recovery .....               | 55           |
| Limbal stem cells .....                    | 231     | Neural stem cell phenotype .....                   | 387          |
| clinical responses to .....                | 232     | Neuroimaging .....                                 | 60           |
| surgical strategies for .....              | 233     | in patient selection/monitoring of delivery .....  | 60           |
| therapeutic use of .....                   | 231     | Oogenesis .....                                    | 289          |
| with penetrating keratoplasty .....        | 236     | cessation in prenatal ovaries .....                | 292          |
| Liver disease .....                        | 139,411 | from human somatic stem cells .....                | 289          |
| bone marrow stem cells for .....           | 411     | <i>in vitro</i> .....                              | 299          |
| hepatocyte transplantation in .....        | 139     | Ovarian surface epithelium (OSE) .....             | 289          |
| transdifferentiation in .....              | 416     | into germ/granulosa cells in human fetal           |              |
| Liver regeneration .....                   | 412     | ovaries .....                                      | 290          |
| models of .....                            | 412     | role of asymmetric division/committed immune       |              |
| Lung progenitor cells .....                | 38      | cells in germ cell development from .....          | 291          |
| analysis of .....                          | 41      | Peripheral blood stem cells .....                  | 189          |
| derivation of .....                        | 38      | harvesting of .....                                | 189          |
| resident type .....                        | 42      | mobilization of .....                              | 189,190      |
| (trans) differentiation of .....           | 40      | pediatric collection of .....                      | 196          |
| Mesenchymal cambial layer cells .....      | 352     |  |              |
| Mesenchymal plasticity .....               | 95      |  |              |

|  |         |  |     |
|--|---------|--|-----|
| role of large volume leukapheresis (LVL) .....   | 195     | Somatic cell plasticity .....              | 327 |
| side effects of .....                            | 197     | potential of .....                         | 327 |
| techniques for collection of .....               | 190     | Somatic cell reprogramming .....           | 326 |
| transplant dose of .....                         | 190     | Stem cell .....                            | 395 |
| Plasticity .....                                 | 121     | experimental studies of .....              | 397 |
| in DC hematopoiesis .....                        | 121     | in therapy .....                           | 395 |
| Pregnancy .....                                  | 379     | proteomic approaches to .....              | 396 |
| trafficking of fetal MSC in .....                | 379     | Stem cell niche .....                      | 164 |
| Premature ovarian failure .....                  | 289     | for plasticity .....                       | 164 |
| animal models for .....                          | 298     | Stem-cell therapy .....                    | 425 |
| immune adaptation/determination of .....         | 296     | for diabetes cure .....                    | 425 |
| immune system vs. brain memory in .....          | 299     | hESC differentiation of .....              | 426 |
| role of immune adaptation in .....               | 289     | Tissue engineering .....                   | 429 |
| treatment for .....                              | 299     | Tissue-specific stem cell therapies .....  | 325 |
| with primary follicles .....                     | 298     | Tissue transplantation .....               | 13  |
| Primate embryonic stem cells .....               | 127     | stem cells in .....                        | 13  |
| epigenetics of .....                             | 129     | TNF locus .....                            | 240 |
| genetic integrity of .....                       | 127     | Transplantation .....                      | 122 |
| Primordial (embryonic) germ cells .....          | 289     | of peripheral tolerance in .....           | 122 |
| origin of .....                                  | 289     | Transplanted cells .....                   | 56  |
| sex determination of .....                       | 289     | cellular/molecular MR imaging of .....     | 56  |
| Progenitors .....                                | 37      | Tumors .....                               | 81  |
| derivation of .....                              | 37      | endogenous neural progenitors for .....    | 81  |
| differentiation of .....                         | 37      | Umbilical cord blood transplantation ..... | 317 |
| in carcinogenesis .....                          | 37      | advantages/disadvantages of .....          | 322 |
| in regeneration .....                            | 37      | applications of .....                      | 322 |
| therapeutic application of .....                 | 37      | clinical studies in .....                  | 318 |
| Regenerative medicine .....                      | 139,274 | cord blood expansion in .....              | 321 |
| Resident airway progenitor cells .....           | 42      | issues of .....                            | 317 |
| Respiratory stem cells .....                     | 37      | sequential based .....                     | 320 |
| application in therapy/biomedical research ..... | 44      | studies in adults .....                    | 319 |
| derivation of .....                              | 37      | studies in children .....                  | 318 |
| differentiation of .....                         | 37      | Umbilical cord stem/progenitor cells ..... | 356 |
| in carcinogenesis .....                          | 37      | Vascularized tissue regeneration .....     | 13  |
| in regeneration .....                            | 37      | in tissue engineering .....                | 16  |
| plasticity of .....                              | 41      | in tissue transplantation .....            | 13  |
| therapeutic application of .....                 | 37      | Vein .....                                 | 357 |
| Sarcopenia .....                                 | 166     | Wharton jelly .....                        | 357 |
| Satellite cells .....                            | 158     |  |     |
| heterogeneity of .....                           | 161     |  |     |
| myogenic regulatory factors in .....             | 160     |  |     |
| Skeletal muscle recycling .....                  | 165     |  |     |
| Skeletal muscle stem cells .....                 | 158     |  |     |